Increased in vivo antibody activity against interferon α, interleukin- 1α, and interleukin-6 after high-dose Ig therapy

Blood

Volumn 90, Issue 6, 1997, Pages 2376-2380

  Ross, Christian ^b   Svenson, Morten ^b   Nielsen, Henrik ^b   Lundsgaard, Charlotte ^b   Hansen, Morten Bagge ^b   Bendtzen, Klaus ^a  

^a Rigshospitalet   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 6;

ADULT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; BINDING AFFINITY; CLINICAL ARTICLE; DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; ISOTOPE LABELING; MALE; PRIORITY JOURNAL;

EID: 0030823544     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.6.2376     Document Type: Article

References (26)

1. Consensus Statement: Intravenous immune globulin: Prevention and treatment of disease (vol 8). NIH Concensus Development Conference, Bethesda, MD, May 21-23, 1990
2. Dwyer JM: Manipulating the immune system with immune globulin. N Engl J Med 326:107, 1992
3. Thornton CA, Griggs RC: Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 35:260, 1994
4. Kaveri SV, Mouthon L, Kazatchkine MD: Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J Neurol Neurosurg Psychiatry 57:6, 1994 (suppl)
5. Andersson UG, Bjšrk L, Skansén-Saphir U, Andersson JP: Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 79:211, 1993
6. Aukrust P, Froland SS, Liabakk NB, Müller F, Nordoy I, Haug C, Espevik T: Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84:2136, 1994
7. Abe Y, Horiuchi A, Miyake M, Kimura S: Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 139:5, 1994
8. Bendtzen K, Hansen MB, Ross C, Svenson M: Cytokine autoantibodies, in Peter JB, Shoenfeld Y (eds): Autoantibodies. Amsterdam, The Netherlands, Elsevier Science, 1996, p 209
9. Svenson M, Hansen MB, Bendtzen K: Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 92:2533, 1993
10. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K: High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest 95:1974, 1995
11. Hansen MB: Human cytokine autoantibodies. Characteristics, test procedures and possible physiological and clinical significance. APMIS 104:1, 1996 (suppl 59)
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger J, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315, 1988
13. Svenson M, Hansen MB, Bendtzen K: Distribution and characterization of autoantibodies to interleukin 1α in normal human sera. Scand J Immunol 32:695, 1990
14. Hansen MB, Svenson M, Diamant M, Bendtzen K: Anti-interleukin-6 antibodies in normal human serum. Scand J Immunol 33:777, 1991
15. Hansen MB, Ross C, Berg K: A sensitive antiviral neutralization bioassay for mesuring antibodies to interferons. J Immunol Methods 127:241, 1990
16. Hansen MB, Svenson M, Bendtzen K: Human anti-interleukin 1α antibodies. Immunol Lett 30:133, 1991
17. Hansen MB, Svenson M, Diamant M, Ross C, Bendtzen K: Interleukin-6 (IL-6) autoantibodies and blood IL-6 measurements. Blood 85:1145, 1995
18. Schedel I, Dreikhausen U, Nentwig B, Höckenschnieder M, Rauthmann D, Balikcioglu S, Coldewey R, Deicher H: Treatment of gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Crit Care Med 19:1104, 1991
19. Saladino RA, Baldwin G, Albert G, Parsonnet J, Gillis Z, Thompson C, Siber GR, Fleisher GR: Effect of human immunoglobulin preparation for intravenous use in a rabbit model of meningococcal endotoxin-induced shock. Crit Care Med 20:816, 1992
20. Ruiz de Souza V, Kaveri SV, Kazatchkine MD: Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases. Clin Exp Rheumatol 11:S33, 1993 (suppl 9)
21. Wortel CH, Van Deventer SJH, Aarden LA, Lygidakis NJ, Büller HR, Hoek FJ, Horikx J, ten Cate JW: Interleukin-6 mediates host defense responses induced by abdominal surgery. Surgery 114:564, 1993
22. Bendtzen K, Hansen MB, Ross C, Poulsen LK, Svenson M: Cytokines and autoantibodies to cytokines. Stem Cells 13:206, 1995
23. Arend WP: Inhibiting the effects of cytokines in human diseases. Adv Intern Med 40:365, 1995
24. Andersson U, Björk L, Skansén-Saphir U, Andersson J: Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 139:21, 1994
25. Arend WP, Leung DY: IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev 139:71, 1994
26. Andersen LS, Petersen J, Svenson M, Bendtzen K: IgG for intravenous use, autologous serum and plasma induce comparable interleukin-1 receptor antagonist liberation from human mononuclear cells: An in vitro phenomenon depending upon plastic adherence. Autoimmunity 22:127, 1995